Genmab
GMAB
229 hedge funds and large institutions have $1.27B invested in Genmab in 2024 Q4 according to their latest regulatory filings, with 51 funds opening new positions, 76 increasing their positions, 75 reducing their positions, and 42 closing their positions.
294% more call options, than puts
Call options by funds: $3.44M | Put options by funds: $872K
21% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 42
12.83% more ownership
Funds ownership: 79.03% → 91.86% (+13%)
2% more funds holding
Funds holding: 224 → 229 (+5)
1% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 75
1% less capital invested
Capital invested by funds: $1.28B → $1.27B (-$11.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$43.9M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$39.4M |
| 3 |
BGIM
Brandywine Global Investment Management
Philadelphia,
Pennsylvania
|
+$35.6M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$30.3M |
| 5 |
Morgan Stanley
New York
|
+$25.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$56.2M |
| 2 |
Capital International Investors
Los Angeles,
California
|
-$40.7M |
| 3 |
HL
Harding Loevner
Bridgewater,
New Jersey
|
-$18.1M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$12.7M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$10.4M |
GMAB Hedge Fund Activity: Q4 2024 in Review
229 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Genmab (GMAB) for Q4 2024, worth a combined $1.27B — down 0.92% from $1.28B a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new GMAB positions and 42 closed out — a net gain of 9 holders — while 76 added to existing stakes and 75 trimmed.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $43.9M. The largest seller was Wellington Management Group, exiting entirely with an estimated $56.2M sold.
- 229 institutional investors held Genmab (GMAB) as of Q4 2024, up from 224 in Q3 2024.
- Funds reported $1.27B of Genmab stock for Q4 2024, down 0.92% quarter-over-quarter.
- 51 funds opened new Genmab positions in Q4 2024 and 42 closed out, a net change of +9 holders.
- The largest Genmab buyer in Q4 2024 was Deep Track Capital, an estimated $43.9M added.
- The largest Genmab seller in Q4 2024 was Wellington Management Group, an estimated $56.2M sold.
Based on aggregated 13F filings for Q4 2024.